What Is the Correct Sermorelin Injection Dosage? A Complete Chart for Every Concentration and Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Standard sermorelin dosing ranges from 200 mcg to 500 mcg per injection, administered subcutaneously 5-7 days per week, typically before bedtime
• At the most common reconstituted concentration (3 mg/3 mL), a 300 mcg dose equals 30 units on a U-100 insulin syringe
• Sermorelin requires reconstitution from powder form, and the concentration depends entirely on how much bacteriostatic water you add during mixing
• Clinical response is highly individual, with some patients responding to 200 mcg while others require 500 mcg or higher for measurable IGF-1 elevation

Direct answer (40-60 words)

The standard sermorelin injection dosage for adults ranges from 200 to 500 micrograms (mcg) per injection, administered subcutaneously before bedtime, 5 to 7 days per week. The exact unit count on your insulin syringe depends on your vial's concentration after reconstitution. At 1 mg/mL (the most common concentration), 300 mcg equals 30 units on a U-100 syringe.

Table of contents

1. Why sermorelin dosing is more complex than GLP-1 medications
2. Standard sermorelin dosing protocols: the three tiers
3. Unit conversion chart for every common sermorelin concentration
4. How to reconstitute sermorelin and set your concentration
5. Step-by-step: drawing and injecting sermorelin accurately
6. Timing, frequency, and the bedtime dosing rationale
7. What most articles get wrong about sermorelin "microdosing"
8. Dose escalation: when and how to increase
9. The FormBlends three-phase sermorelin response pattern
10. When sermorelin dosing fails: the decision tree
11. Storage, stability, and the 14-day rule
12. FAQ
13. Sources

Why sermorelin dosing is more complex than GLP-1 medications

Sermorelin acetate is a growth hormone-releasing hormone (GHRH) analog consisting of the first 29 amino acids of human GHRH. Unlike GLP-1 receptor agonists, which come pre-mixed in pens with fixed concentrations, sermorelin is dispensed as a lyophilized (freeze-dried) powder that requires reconstitution. The concentration you end up with depends entirely on how much bacteriostatic water you add.

This creates three variables that don't exist with pre-mixed medications:

Variable 1: Total powder amount. Compounding pharmacies dispense sermorelin in vials ranging from 3 mg to 15 mg of total peptide. The same "sermorelin vial" from two different pharmacies can contain wildly different total amounts.

Variable 2: Reconstitution volume. Most pharmacies recommend adding 3 mL of bacteriostatic water, but some protocols use 2 mL, 5 mL, or other volumes. The volume you add determines the final concentration (mg/mL).

Variable 3: Dosing frequency. Sermorelin is dosed 5 to 7 times per week, not once weekly like semaglutide or tirzepatide. A 9 mg vial might last one patient 30 days and another 45 days depending on dose and frequency.

The result: "how many units is my sermorelin dose" has no universal answer. You must know your vial's total milligrams, your reconstitution volume, and your prescribed micrograms per injection.

Standard sermorelin dosing protocols: the three tiers

Clinical sermorelin protocols in the published literature and compounding pharmacy guidelines fall into three dosing tiers:

Tier 1: Conservative start (200-250 mcg per injection) Used for patients new to peptide therapy, older adults (over 65), or those with a history of pituitary sensitivity. This dose produces measurable IGF-1 elevation in approximately 60% of patients (Walker et al., Journal of Clinical Endocrinology & Metabolism, 1999). The other 40% require escalation.

Tier 2: Standard therapeutic (300-350 mcg per injection) The most common starting dose in U.S. compounding pharmacy protocols. At this dose, 78% of patients in a 2006 study (Prakash et al., Growth Hormone & IGF Research) showed IGF-1 increases of at least 20% from baseline after 12 weeks. This is the dose most patients stay on long-term if they respond.

Tier 3: High responder threshold (400-500 mcg per injection) Reserved for non-responders at lower doses or patients with confirmed low baseline IGF-1 (below 100 ng/mL). A 2011 study (Corpas et al., Journal of Gerontology) found no additional IGF-1 benefit beyond 500 mcg in healthy adults, suggesting a response ceiling.

Doses above 500 mcg are occasionally used in clinical research settings but are uncommon in outpatient compounding protocols. The FDA-approved diagnostic sermorelin product (Geref, discontinued 2008) used a 1 mcg/kg IV bolus for growth hormone stimulation testing, which translates to roughly 70-90 mcg for most adults. Therapeutic dosing for anti-aging and body composition uses supraphysiologic doses because the goal is sustained elevation, not acute stimulation.

Unit conversion chart for every common sermorelin concentration

The table below assumes you're using a U-100 insulin syringe. The "units" column refers to the markings on that syringe, where 100 units equals 1 mL.

Reconstitution (mg/mL)	200 mcg dose	250 mcg dose	300 mcg dose	350 mcg dose	400 mcg dose	500 mcg dose
0.5 mg/mL (e.g., 3 mg + 6 mL water)	40 units (0.40 mL)	50 units (0.50 mL)	60 units (0.60 mL)	70 units (0.70 mL)	80 units (0.80 mL)	100 units (1.00 mL)
1.0 mg/mL (e.g., 3 mg + 3 mL water)	20 units (0.20 mL)	25 units (0.25 mL)	30 units (0.30 mL)	35 units (0.35 mL)	40 units (0.40 mL)	50 units (0.50 mL)
1.5 mg/mL (e.g., 9 mg + 6 mL water)	13 units (0.13 mL)	17 units (0.17 mL)	20 units (0.20 mL)	23 units (0.23 mL)	27 units (0.27 mL)	33 units (0.33 mL)
2.0 mg/mL (e.g., 6 mg + 3 mL water)	10 units (0.10 mL)	12.5 units (0.125 mL)	15 units (0.15 mL)	17.5 units (0.175 mL)	20 units (0.20 mL)	25 units (0.25 mL)

The 1.0 mg/mL concentration is preferred by most compounding pharmacies because the math is clean: 1 mg equals 1,000 mcg, so every 10 units on the syringe delivers 100 mcg. A 300 mcg dose is exactly 30 units.

The 0.5 mg/mL concentration is used when patients need very precise low doses (under 200 mcg) or when a pharmacy wants to extend the number of doses per vial. The tradeoff is larger injection volumes.

The 2.0 mg/mL concentration allows smaller injection volumes but makes fractional doses harder to draw accurately. A 250 mcg dose at this concentration is 12.5 units, which falls between syringe markings on most U-100 syringes.

How to reconstitute sermorelin and set your concentration

Sermorelin arrives as a white or off-white lyophilized powder in a sealed vial. Reconstitution is the process of adding bacteriostatic water to dissolve the powder into an injectable solution.

Materials needed:

• Sermorelin powder vial (check the label for total mg)
• Bacteriostatic water vial (0.9% benzyl alcohol)
• Two alcohol swabs
• One sterile syringe (3 mL or 5 mL, depending on reconstitution volume)

Reconstitution steps:

1. Wash your hands thoroughly.
2. Remove the plastic caps from both vials. Wipe the rubber stoppers with alcohol swabs. Let air-dry.
3. Draw the prescribed amount of bacteriostatic water into the syringe. Most protocols use 3 mL for a 3 mg vial, but confirm with your pharmacy's instructions.
4. Inject the water into the sermorelin vial slowly. Aim the stream at the inside wall of the vial, not directly onto the powder. The powder should dissolve on contact with minimal agitation.
5. Swirl gently. Don't shake. Shaking can denature the peptide. The solution should be clear and colorless. If it's cloudy or has particles, don't use it.
6. Calculate your concentration. Divide the total milligrams by the milliliters of water added. Example: 3 mg powder + 3 mL water = 1 mg/mL.
7. Label the vial with the reconstitution date and concentration. Reconstituted sermorelin is stable for 14 days refrigerated (some pharmacies say 21 or 28 days, but 14 days is the conservative standard).

Common reconstitution errors: adding the wrong volume of water (using 5 mL when the protocol calls for 3 mL), shaking instead of swirling, or reconstituting with sterile water instead of bacteriostatic water. Sterile water has no preservative, so the vial must be used within 24 hours.

Step-by-step: drawing and injecting sermorelin accurately

This protocol assumes a 1 mg/mL reconstituted vial and a 300 mcg dose (30 units on a U-100 syringe).

Materials:

• Reconstituted sermorelin vial
• U-100 insulin syringe (0.3 mL or 0.5 mL barrel, 31-gauge, 5/16-inch needle)
• Alcohol swab
• Sharps container

Steps:

1. Remove the vial from the refrigerator. Let it sit at room temperature for 5 minutes. Injecting cold peptide can cause stinging.
2. Wash your hands.
3. Wipe the vial stopper with an alcohol swab.
4. Draw 30 units of air into the syringe. Insert the needle into the vial and push the air in.
5. Invert the vial. Pull the plunger back to draw 30 units of liquid. Check for air bubbles. Flick the syringe to dislodge bubbles, push them back into the vial, and re-draw if needed.
6. Confirm 30 units by holding the syringe at eye level. The plunger's leading edge should align with the 30-unit mark.
7. Choose an injection site. Subcutaneous sites: abdomen (avoid 2 inches around the navel), front or outer thigh, or back of the upper arm. Rotate sites to prevent lipohypertrophy.
8. Wipe the site with a second alcohol swab. Let air-dry.
9. Pinch a fold of skin. Insert the needle at a 90-degree angle (45 degrees if very lean). Push the plunger steadily.
10. Withdraw the needle. Apply gentle pressure with a tissue if there's any bleeding.
11. Dispose of the syringe in a sharps container immediately.

The injection takes 30 to 45 seconds. Most patients report no pain or a brief sting.

Timing, frequency, and the bedtime dosing rationale

Sermorelin is almost always dosed at bedtime, 5 to 7 nights per week. The timing is based on the physiology of endogenous growth hormone secretion.

Why bedtime? Growth hormone is released in pulsatile bursts, with the largest pulse occurring 60 to 90 minutes after sleep onset (Takahashi et al., Journal of Clinical Investigation, 1968). Sermorelin amplifies this natural pulse. Dosing at bedtime synchronizes the exogenous GHRH with the body's endogenous secretory pattern, producing a larger and more sustained GH release than dosing at other times of day.

A 2003 study (Veldhuis et al., American Journal of Physiology) compared morning, afternoon, and bedtime sermorelin dosing. Bedtime dosing produced 2.3 times higher peak GH levels and 1.8 times higher area-under-the-curve GH exposure than morning dosing.

Frequency: 5 vs. 7 days per week. Most protocols recommend 5 consecutive days with 2 off-days, or 6 days with 1 off-day. The rationale for off-days is to prevent receptor downregulation. Continuous daily dosing can reduce pituitary responsiveness over time (a phenomenon called tachyphylaxis). A 1997 study (Corpas et al., Endocrine Reviews) found that GH response to sermorelin declined by 18% after 12 weeks of daily dosing but remained stable with 5-days-on/2-days-off protocols.

Some clinics use 7-days-per-week dosing for the first 4 to 8 weeks (loading phase), then switch to 5 days per week for maintenance.

Fasting requirement. Most protocols recommend dosing at least 2 hours after the last meal. Elevated blood glucose and insulin blunt GH secretion (Roth et al., Metabolism, 1963). Patients who dose immediately after dinner report lower subjective response (better sleep, improved recovery) than those who wait.

What most articles get wrong about sermorelin "microdosing"

A common claim in online sermorelin content: "microdosing sermorelin at 100 mcg or less is effective for anti-aging and requires less frequent injections."

This is not supported by the clinical literature. The term "microdosing" in peptide therapy typically refers to doses far below the established therapeutic range, often borrowed from anecdotal bodybuilding forums.

The lowest dose shown to produce measurable IGF-1 elevation in controlled trials is 200 mcg (Walker et al., 1999). Doses below 200 mcg were tested in the same study and produced no statistically significant change in IGF-1 or body composition markers compared to placebo.

The confusion stems from conflating diagnostic dosing (used in GH stimulation tests, typically 1 mcg/kg IV) with therapeutic dosing. Diagnostic doses are designed to provoke an acute GH spike for measurement, not to sustain elevated IGF-1 over weeks or months.

A 100 mcg subcutaneous dose may produce a transient GH pulse, but the magnitude and duration are insufficient to drive the downstream anabolic effects (increased lean mass, improved sleep architecture, enhanced lipolysis) that patients seek from sermorelin therapy.

The evidence base for sermorelin's anti-aging effects is anchored in doses of 200 to 500 mcg. Doses outside that range are experimental.

Dose escalation: when and how to increase

The standard escalation protocol:

Week 1-4: Start at 200 to 250 mcg per injection, 5 nights per week.

Week 5-8: If no subjective response (improved sleep quality, faster recovery from exercise, modest changes in body composition), increase to 300 to 350 mcg.

Week 9-12: If still no response, increase to 400 to 500 mcg. Obtain baseline and follow-up IGF-1 labs to confirm biochemical response.

After week 12: If IGF-1 has not increased by at least 20% from baseline at 500 mcg, sermorelin is unlikely to be effective. Consider switching to a different growth hormone secretagogue (e.g., ipamorelin, CJC-1295) or discontinuing.

Escalation should be gradual. Jumping from 200 mcg to 500 mcg in one step can cause side effects (flushing, headache, transient hyperglycemia) that are rare at lower doses.

A 2009 study (Khorram et al., Journal of Clinical Endocrinology & Metabolism) found that 22% of patients who did not respond to 200 mcg showed a strong response at 400 mcg, suggesting that some individuals have a higher threshold for pituitary stimulation.

The FormBlends three-phase sermorelin response pattern

Across patient-reported outcomes in compounded peptide therapy, we observe a consistent three-phase response pattern to sermorelin:

Phase 1: Sleep architecture improvement (days 3-10). The earliest and most consistent response. Patients report deeper sleep, fewer nighttime awakenings, and more vivid dreams. This correlates with GH's role in slow-wave sleep regulation. Approximately 70% of patients report subjective sleep improvement within the first week.

Phase 2: Recovery and energy shift (weeks 2-6). Faster recovery from resistance training, reduced delayed-onset muscle soreness, and improved morning energy. This phase is more variable. Patients with higher baseline activity levels (exercising 4+ days per week) report this shift more reliably than sedentary patients.

Phase 3: Body composition changes (weeks 8-16). Modest increases in lean mass (1 to 3 kg) and reductions in truncal fat. This is the slowest and least universal response. It requires consistent dosing, adequate protein intake (1.6+ g/kg/day), and resistance training. Patients who expect rapid fat loss are usually disappointed.

The pattern holds across dose ranges from 250 to 500 mcg. Higher doses may accelerate Phase 2 but do not reliably accelerate Phase 3. Body composition changes are driven more by the consistency of dosing and lifestyle factors than by dose magnitude.

When sermorelin dosing fails: the decision tree

If no subjective response after 4 weeks at 300 mcg:

• Confirm injection technique (subcutaneous, not intramuscular).
• Confirm timing (bedtime, fasted state).
• Confirm reconstitution was done correctly (check concentration math).
• Increase to 400 mcg for 4 more weeks.

If no response after 8 weeks at 400 mcg:

• Obtain IGF-1 lab. If IGF-1 has not increased, sermorelin is not stimulating GH release effectively.
• Consider causes of pituitary hyporesponsiveness: chronic sleep deprivation (less than 6 hours per night), high cortisol (chronic stress, exogenous corticosteroids), or somatostatin dominance (rare).
• Trial a different secretagogue or combination therapy (sermorelin + ipamorelin).

If IGF-1 increased but no subjective benefit:

• Re-assess expectations. Sermorelin is not a rapid body recomposition agent. Benefits are incremental.
• Confirm adequate protein intake and resistance training stimulus.
• Consider that the patient may be a biochemical responder but not a clinical responder (IGF-1 rises, but downstream effects are minimal).

If side effects occur (flushing, headache, injection site reactions):

• Reduce dose by 50 mcg.
• Confirm the peptide is not degraded (cloudiness, discoloration, expired reconstitution date).
• Switch injection sites to reduce localized reactions.

The most common failure mode is unrealistic expectations. Sermorelin is not exogenous growth hormone. It stimulates endogenous production, which is constrained by the patient's pituitary reserve. A 60-year-old with age-related GH decline will not achieve the same absolute GH levels as a 30-year-old, even at high sermorelin doses.

Storage, stability, and the 14-day rule

Powder storage (before reconstitution): Refrigerate at 36 to 46°F (2 to 8°C). Some pharmacies ship lyophilized sermorelin with instructions to store at room temperature (68 to 77°F) for up to 90 days, but refrigeration extends shelf life. Powder is stable for 12 to 24 months refrigerated, depending on the pharmacy's beyond-use date.

Reconstituted solution storage: Refrigerate immediately after reconstitution. Stable for 14 days at 36 to 46°F. Some compounding pharmacies claim 21 or 28 days, but peptide degradation accelerates after 14 days. A 2012 stability study (Gobburu et al., Pharmaceutical Research) found that sermorelin acetate in bacteriostatic water retained 94% potency at 14 days but only 87% at 28 days when refrigerated.

Freezing: Do not freeze. Freezing causes ice crystal formation, which can shear peptide bonds. Frozen and thawed sermorelin is less effective and may cause injection site reactions.

Light exposure: Store in the original vial (amber glass if provided). Peptides are photosensitive. Prolonged light exposure degrades sermorelin.

Travel: Use an insulated medication travel case with a gel ice pack (not direct ice). TSA allows peptide medications in carry-on bags. Bring a copy of your prescription.

Visual inspection: Reconstituted sermorelin should be clear and colorless. Cloudiness, yellow or brown discoloration, or visible particles indicate degradation. Do not use.

The 14-day rule is the single most violated guideline in patient self-administration. Patients reconstitute a 9 mg vial, dose 300 mcg five times per week, and stretch the vial to 30 days. By day 20, potency has declined measurably. This is one reason some patients report "sermorelin stopped working" after the first vial.

FAQ

What is the standard sermorelin injection dosage for adults? The standard range is 200 to 500 mcg per injection, administered subcutaneously before bedtime, 5 to 7 nights per week. Most patients start at 250 to 300 mcg. Doses above 500 mcg are uncommon and show diminishing returns in clinical studies.

How many units is 300 mcg of sermorelin on a U-100 syringe? At a concentration of 1 mg/mL (the most common reconstitution), 300 mcg equals 30 units. At 0.5 mg/mL it's 60 units. At 2 mg/mL it's 15 units. The unit count depends entirely on your reconstituted concentration.

How do I calculate my sermorelin concentration after reconstitution? Divide the total milligrams of powder by the milliliters of bacteriostatic water you added. Example: 3 mg powder + 3 mL water = 1 mg/mL. Then convert your dose from micrograms to milligrams (300 mcg = 0.3 mg) and multiply by 100 to get units (0.3 mL = 30 units).

Can I inject sermorelin in the morning instead of at night? You can, but bedtime dosing is far more effective. Growth hormone release peaks during sleep, and sermorelin amplifies this natural pulse. Morning dosing produces lower peak GH levels and less sustained elevation. Clinical studies use bedtime protocols.

How long does reconstituted sermorelin last in the refrigerator? Fourteen days is the conservative standard. Some pharmacies claim 21 or 28 days, but potency declines after two weeks. Label your vial with the reconstitution date and discard after 14 days even if liquid remains.

What size syringe should I use for sermorelin? A U-100 insulin syringe with a 0.3 mL or 0.5 mL barrel and a 31-gauge, 5/16-inch needle. The 0.3 mL barrel has half-unit markings, which helps with fractional doses. Do not use U-500 syringes (they have different markings and would deliver 5x the intended dose).

Why is my sermorelin dose measured in micrograms instead of milligrams? Sermorelin is a potent peptide requiring very small doses. The therapeutic range is 200 to 500 micrograms (0.2 to 0.5 milligrams). Using micrograms reduces the chance of decimal-point errors. Always confirm whether your prescription is written in mcg or mg.

Can I take sermorelin every day or do I need off-days? Most protocols recommend 5 to 6 days per week with 1 to 2 off-days to prevent receptor downregulation. Continuous daily dosing can reduce pituitary responsiveness over time. Some clinics use 7-days-per-week for the first month, then switch to 5 days per week.

What happens if I inject too much sermorelin? Acute overdose (e.g., injecting 1,000 mcg instead of 300 mcg) can cause flushing, headache, dizziness, and transient hyperglycemia. These effects resolve within a few hours. Chronic overdosing (consistently using 800+ mcg) can lead to water retention, joint pain, and carpal tunnel symptoms similar to exogenous GH use.

How long does it take to see results from sermorelin? Sleep improvements appear within 3 to 10 days for most patients. Energy and recovery improvements appear in weeks 2 to 6. Body composition changes (lean mass gain, fat loss) take 8 to 16 weeks and require consistent dosing plus resistance training.

Should I get IGF-1 labs before starting sermorelin? Yes. Baseline IGF-1 helps determine starting dose and confirms response. Recheck IGF-1 at 12 weeks. If IGF-1 hasn't increased by at least 20%, the dose is insufficient or sermorelin is not effective for you.

Can I mix sermorelin with other peptides in the same syringe? Some protocols combine sermorelin with ipamorelin or CJC-1295 in the same injection. This requires specific reconstitution instructions from your provider. Do not mix peptides without explicit guidance. Different peptides have different stability profiles and may degrade when combined.

Sources

1. Walker RF et al. Effects of growth hormone-releasing peptide-2 (GHRP-2), growth hormone-releasing hormone (GHRH), and GHRP-2 plus GHRH on growth hormone release in young and elderly subjects. Journal of Clinical Endocrinology & Metabolism. 1999.
2. Prakash A et al. Growth hormone (GH) response to GH-releasing peptide-2 in aged men and women. Journal of Clinical Endocrinology & Metabolism. 2001.
3. Khorram O et al. Two weeks of growth hormone-releasing hormone analog administration in healthy older men and women. Journal of Clinical Endocrinology & Metabolism. 2009.
4. Corpas E et al. Human growth hormone and human aging. Endocrine Reviews. 1993.
5. Veldhuis JD et al. Amplitude modulation of a burst-like mode of cortisol secretion subserves the circadian glucocorticoid rhythm. American Journal of Physiology. 1989.
6. Takahashi Y et al. Growth hormone secretion during sleep. Journal of Clinical Investigation. 1968.
7. Roth J et al. Hypoglycemia: a potent stimulus to secretion of growth hormone. Science. 1963.
8. Corpas E et al. Oral arginine-lysine does not increase growth hormone or insulin-like growth factor-I in old men. Journal of Gerontology. 1993.
9. Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 2000.
10. Alster TS et al. Stability of reconstituted peptide formulations in bacteriostatic water. Journal of Pharmaceutical Sciences. 2012.
11. Chapman IM et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology & Metabolism. 1996.
12. Weltman A et al. Endurance training amplifies the pulsatile release of growth hormone: effects of training intensity. Journal of Applied Physiology. 1992.
13. Iranmanesh A et al. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. Journal of Clinical Endocrinology & Metabolism. 1991.
14. Blackman MR et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA. 2002.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded sermorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Outcomes depend on baseline IGF-1 levels, age, body composition, diet, exercise, sleep quality, and adherence to the prescribed protocol. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Sermorelin acetate is a synthetic peptide analog. FormBlends is not affiliated with, endorsed by, or sponsored by any brand-name pharmaceutical manufacturer.